We have recently identi®ed an internal tandem duplication of the human Flt3 gene in approximately 20% of acute myeloid leukemia (AML) cases. In the present study, the wild-type and the mutant Flt3 genes were transfected into two IL- 
Introduction
The Flk2/Flt3 receptor, a class III receptor tyrosine kinase (RTK) together with KIT, FMS and receptors for platelet-derived growth factors (PDGFs), is expressed in multipotential hematopoietic stem cell and progenitors, suggesting that its ligand is critical for stem cell development and dierentiation (Rosnet et al., 1991a (Rosnet et al., ,b, 1993 Matthews et al., 1991; Cadena and Gill, 1992; Yarden and Ullrich, 1988) . Targeted disruption of the Flt3 gene in mice produced de®ciencies in primitive lymphoid and hematopoietic progenitors, suggesting an essential role for the gene (Mackarehtschian et al., 1995) . Flt3 ligand caused a proliferative response in a considerably high percentage of AML cases (Piacibello et al., 1995; Mckenna et al., 1996; Lisovsky et al., 1996; Drexler, 1996) . This suggests that the RTK is potentially important not only for normal hematopoiesis but also for leukemia cell proliferation. Furthermore, it was recently revealed that internal tandem duplication in the juxtamembrane domain of the Flt3 receptor (Flt3/ITD) occurs in approximately 20% of AML cases . The Flt3/ITD has also been reportedly correlated with disease progression from antecedent myelodysplasia (Horiike et al., 1997) . Thus the amounting evidences indicate that the Flt3 receptor and the ligand interaction may play critical roles in leukemia onset, development, and progression.
Several groups have reported the intracellular signal components activated by wild-type Flt3 with ligand stimulation. One group has examined the putative signal components of wild-type Flt3 receptor using chimeric molecules containing the extracellular domain of CSF-1 receptor (c-FMS) fused to the transmembrane and cytoplasmic domains of mouse Flt3. They proposed the ability to tyrosine-phosphorylate GAP, PLCg, Vav, Shc, and the p85 subunit of PI3 kinase and to associate with Grb2, PLCg, the p85 subunit of PI3 kinase, Shc, Fyn, Src (Mercedes et al., 1993) . Another group has shown that CBL, a proto-oncogene product, in human myeloid cell lines and CBLB, the CBL-related protein, in human early B cell lines were tyrosine-phosphorylated on Flt3 ligand stimulation of endogenous Flt3, and associated with the p85 subunit of PI3 kinase (Lavagna-SeÁ venier et al., 1998a,b) . In a very recent report which appeared while this paper was under review, wild-type human Flt3 caused phosphorylation of mitogen-activated protein (MAP) kinase and minimal cell growth with Flt3 ligand stimulation in IL-3-dependent hematopoietic progenitor BA/F3 cells (Zhang et al., 1999) . These may be critical issues for understanding the role of normal signals from wild-type Flt3 receptors in hematopoietic cell growth and the escape from apoptosis, leading to elucidation of the mechanism of leukemogenesis. Little is known, however, about the dierences of activation of the intracellular signal components between via wild-type Flt3 and via Flt/ITD, and biological relevance of Flt3/ITD.
In the present study, we introduced full-length wildtype and mutant Flt3 receptor genes into two IL-3-dependent hematopoietic progenitors, 32D and BA/F3 cells to prove the existence of constitutive activation of possible signal components by Flt3/ITD. We also examined the components of two major signal transduction pathways, MAP kinase pathway and STAT (signal transducers and activators of transcription) pathway. In both cells, expression of mutant Flt3 caused autonomous cell growth and activation of MAP kinase and STAT5. In contrast, wild-type Flt3 with Flt3 ligand stimulation transduces only MAP kinase but not STAT5 and causes minimal cell growth. In addition, dual constitutive activation of MAP kinase and STAT5 were shown in all clinically isolated AML blasts with Flt3/ITD examined. These experiments clearly revealed, for the ®rst time, the potential functions of mutant Flt3 receptor tyrosine kinase in hematopoietic malignancies.
Results
Both STAT5 activation and abrogation of IL-3 dependency are mutant Flt3 specific in BA/F3 cells
We have studied the signal transduction cascades caused by the Flt3/ITD derived from AML patients. We ®rstly transfected one wild-type Flt3 and 2 mutant Flt3 expression vectors (Wild, Mut1 and Mut2 as shown in Figure 1a ) by electroporation into BA/F3 cells, IL-3-dependent murine multipotential cells derived from pro-B. Single clones of stable transfectants were established by the selection with neomycin in the presence of IL-3. Every ®ve clones from respective Wild, Mut1 and Mut2 were con®rmed for Flt3 expression on cell surface by¯ow cytometric analysis using anti-Flt3 antibody and tested for cell growth. Since essentially the same results were obtained among respective ®ve clones, one representative clone of respective transfectant (Wild, Mut1 and Mut2, respectively) was used for further analysis. Because similar results were obtained through all those experiments between Mut1 and Mut2, the representative data from Mut1 are shown in this report. We concomitantly designated Wild and Mut1 transfectant as wt Flt3 ± BAF3 and mut Flt3 ± BAF3, respectively. A representative data of Flt3 expression were shown in Figure 1b .
Upon deprivation of IL-3, mut Flt3 ± BAF3 proliferated and approximately 90% of the cells remained viable in the absence of IL-3 (Figure 1c,d) . The cell growth rate and viability were comparable to that of the parental BA/F3 cells (designated as parental BAF3) growing exponentially in complete medium containing Signal cascades activated by Flt3 F Hayakawa et al IL-3 (data not shown). In contrast, wt Flt3 ± BAF3 which was deprived of IL-3 and cultured with Flt3 instead survived but proliferated minimally by approximately one-fourth of mut Flt3 ± BAF3 and the viability was reduced by approximately 70% (Figure 1c,d ). Without IL-3, parental BA/F3 cells in the presence or absence of Flt3 ligand exhibited essentially the same growth and viability curves as wt Flt3 ± BAF3 without cytokine (data not shown).
We then examined the eects of mutant Flt3 on the constitutive activation of the signal cascades. Wt or mut Flt3 ± BAF3 were deprived of IL-3 for 6 h and then restimulated with Flt3 ligand. Phosphorylation of Flt3 was investigated as previously described . As shown in Figure 2a , mutant Flt3 was phosphorylated independent of ligand, while wild-type Flt3 was phosphorylated with ligand stimulation only. Activation (phosphorylation) of MAP kinase (ERK1 and ERK2) was examined with the mobility shift of the phosphorylated form of MAP kinase by low-bis SDS ± PAGE followed by Western blot analysis (Towatari et al., 1997) . In mut Flt3 ± BAF3, constitutive phosphorylation of both ERK1 and ERK2 was observed without ligand stimulation (Figure 2b ). Phosphorylation of MAP kinase occurred on Flt3 ligand stimulation in wt Flt3 ± BAF3 (Figure 2b ). Nuclear extracts were subjected to Western blotting and gel shift assay to examine the activation of STAT5, a potential signaling molecule for Flt3. Western blotting with anti-phospho STAT5 antibody showed constitutive Figure 2 Ligand-independent phosphorylation of mutant Flt3, phosphorylation of ERK1 and ERK2 and mutant-speci®c activation of STAT5 in BA/F3 transfectants. Cells were deprived of IL-3 for 6 h and then restimulated with 100 ng/mL of IL-3 or Flt3 ligand for 10 min or left untreated. (a) Flt3 phosphorylation. One mg of whole cell lysate was immunoprecipitated with antiFlt3 antibody. The immunoprecipitates were resolved by 8% SDS ± PAGE and subjected to immunoblot analysis probed with antiphosphotyrosine (pTyr) antibody (upper). The same membrane was stripped and reprobed with anti-Flt3 antibody (lower). (b) ERK1 and ERK2 phosphorylation. Forty mg of whole cell lysate was separated by electrophoresis with SDS-polyacrylamide gel containing low bis acrylamide (low bis SDS ± PAGE) and subjected to immunoblot analysis probed with anti-ERK1 and ERK2 antibody. Phosphorylated or dephosphorylated forms of ERK1 and ERK2 were indicated by arrows. (c) Tyrosyl-phosphorylation of STAT5. One hundred mg of nuclear extract was subjected to 8% SDS ± PAGE and immunoblotted with anti-phospho STAT5 antibody (upper). The same membrane was stripped and reprobed with anti-STAT5 antibody (lower). Inhibition of MAP kinase pathway by PD98059 induced cell death in wt Flt3 ± BAF3 and growth suppression in mut Flt3 ± BAF3
To determine the eect of MAP kinase phosphorylation caused by mut Flt3 or Flt3 ligand on cell growth, we used PD98059 (Calbiochem, San Diego, CA, USA) as a speci®c inhibitor of MAP kinase kinase (MEK) (Pang et al., 1995) . Preincubation with PD98059 prior to Flt3 ligand stimulation completely inhibited the Flt3 ligand-oriented activation of MAP kinase in wt Flt3 ± BAF3. Addition of PD98059 also suppressed constitutive phosphorylation of MAP kinase in mut Flt3 ± BAF3, although the phosphorylated form of MAP kinase became visible through longer exposure. (Figure  3a ). In accordance with MAP kinase phosphorylation, under these conditions, wt Flt3 ± BAF3 could not survive, and mut Flt3 ± BAF3 could grow only at 70% the rate of untreated cells (Figure 3b ). These results suggest that the activation of MAP kinase may be deeply involved in the Flt3 ligand-dependent and mut Flt3-dependent cell growth.
The introduction of tandem-duplicated Flt3 but not wild-type Flt3 into 32D cells causes IL-3 independency and constitutive activation of STAT5
To con®rm the eects of mutant Flt3 on the signal components and resulting cell growth, we transfected Mut1 and Mut2 into another IL-3-dependent early progenitor cell line, 32D. After obtaining the appropriate clones from single colonies and con®rming the expression of Flt3 (Figure 4a ), cell growth was examined in the absence of IL-3. Since the clones transfected with Mut1 and Mut2 exhibited essentially the identical growth curve, a representative data from the clone with Mut1 (designated as mut Flt3 ± 32D) were shown. Similar to BA/F3 transfectants, mut Flt3 ± 32D proliferated in the absence of IL-3, while 32D cells transfected with wild-type Flt3 (designated as wt Flt3 ± 32D) showed minimal growth even in the presence of Flt3 ligand (Figure 4b ). The phosphorylation of MAP kinase and DNA-binding activity of STAT5 in the 32D transfectants were also analysed in the same way as in BA/F3 transfectants. Phosphorylation of MAP kinase (ERK1 and ERK2) and activation of STAT5 were both constitutively observed in mut Flt3 ± 32D, while only MAP kinase but not STAT5 was stimulated with Flt3 ligand in wt Flt3 ± 32D deprived of IL-3 (Figure 4c,d ). The signal cascades and the acquirement of IL-3 independency via normal and tandem-duplicated Flt3 receptor are equivalent between BA/F3 and 32D transfectants.
Both STAT5 and MAP kinase are constitutively phosphorylated in clinically isolated AML blasts with Flt3/ITD
Finally, we examined the phosphorylation of STAT5 and ERK2 as described previously (Hayakawa et al., 1998) in ten AML blasts which had already been shown to have tandem duplication in Flt3 gene . In all ten cases, constitutive phosphorylation of both STAT5 and ERK2 were observed. Representative data from six cases were shown in Figure 5 . JAKs is individually required for activation of STATs (Vignais et al., 1996) . A recent report showed PDGFinduced activation of STAT5 and its direct binding to three tyrosine residues of the PDGF b-receptor; two of three tyrosine residues are located on the juxtamembrane domain (Valgeirsdottir et al., 1998) . However, the binding of STAT5 or JAK2, which is known to bind erythropoietin (Epo) receptor and phosphorylate STAT5, to either wild-type or mutant Flt3 was not detected by co-immunoprecipitation analysis (unpublished data). IL-3 receptor binds Lyn at the membraneproximal region (amino acids 457 ± 465) of its common beta subunit and regulates the activity of Lyn in leukemia cell lines (Adachi et al., 1999; Torigoe et al., 1992) . In a recent report, the abilities of Lyn to bind Epo receptor at the membrane-proximal region and to induce tyrosine-phosphorylation of Epo receptor and STAT5 were shown in vitro and in Cos 7 cells. The association of Lyn with Epo receptor was shown also in 32D cells transfected with Epo receptor (Chin et al., 1998) . Thus, certain members of Src family may bind to mutant Flt3 at the tandem-duplicated juxtamembrane domain and signal through STAT5 activation. Following tandem duplication of Flt3 receptors, the mutant Flt3 per se was sucient to abrogate cytokine dependency for cell expansion of multipotential pro-Bderived BA/F3 cells and early myeloid progenitor 32D cells. The fact that PD98059, a MAP kinase kinase inhibitor, suppressed cell growth revealed that activation of MAP kinase is necessary for maximal cell expansion caused by mutant Flt3 in this assay system. The dierential eect of PD98059 on cell death between wt and mut Flt3 ± BAF3 may be derived from the dierential activation status of STAT5 in these cells. Since there are other potential STAT family members to be elucidated as mut-Flt3-speci®c targets, we cannot conclude that STAT5 is exclusively activated by mutant Flt3 but not normal Flt3 ligand stimulation. Simultaneous activation of the MAP kinase pathway and STATs pathway including STAT5 may cooperatively abrogate IL-3 requirement. This is in line with the previous reports on the involvement of MAP kinase and STAT5 in IL-3 and GM-CSF signaling cascades by the use of IL-3-dependent cell lines: MAP kinase is critical for the prevention of apoptosis and STAT5 for cell growth in association with MAP kinase (Perkins et al., 1996; Mui et al., 1996) and recent reports on the crucial role of STAT5 in cytokinedependent growth and antiapoptosis of hematopoietic cells through transcriptional regulation of the cyclin D1 and Bcl-XL (Dumon et al., 1999; Matsumura et al., 1999; Socolovsky et al., 1999) . Furthermore, very recently, a group has shown Flt3 ligand caused slower cell proliferation than that obtained by IL-3 in BA/F3 cells transfected with wild-type Flt3 receptor. They also showed phosphorylation of MAP kinase on ligand stimulation in transfected BA/F3 cells, and the addition of PD98059 inhibited both cell growth and phosphorylation of MAP kinase. (Zhang et al., 1999) . This is consistent with our results, although they did not examine the activation of JAK ± STAT pathway via Flt3. Finally, dual activation of MAP kinase (ERK2) and STAT5 was observed in all ten AML isolates possessing the mutation of Flt3 examined. This was consistent with results in experimental models; MAP kinase and STAT5 were constitutively activated in mutant Flt3 transfectants. In previous reports, we showed that 56 and 80% of AML cases exhibited constitutive activation of classical MAP kinase and STAT5, respectively. No correlation was observed between constitutive activation of MAP kinase and STAT5 activation (Hayakawa et al., 1998) , suggesting that each pathway is activated speci®cally in a large percentage of individual AML cases. Our results indicate that STAT5 and classical MAP kinase are dually activated in AML with Flt3/ITD with high frequency relative to the other AML cases. This suggests that Flt3/ ITD causes activation of both sTAT5 and classical MAP kinase in clinical AML blasts.
The present ®ndings, taken together with the fact that mutations are frequently acquired during the development of AML from myelodysplasia, suggest the functional growth advantage resulting from the constitutive activation of the signal cascades, as mentioned above, may be critical for progression of leukemia.
Materials and methods

Cells
BA/F3 and 32D cells were maintained in RPMI 1640 containing 10% fetal calf serum (FCS) and 5 ng/mL of recombinant murine IL-3 kindly provided by Kirin Brewery Co. (Tokyo, Japan). Ten AML samples, previously frozen by a controlled-rate freezer to 7808C and stocked in liquid nitrogen, were subjected to quick thawing and extraction of whole cell lysates. The analysed samples were included three M1, three M2, one M3, one M4 and two M5 according to the French-American-British (FAB) classi®cation. The internal tandem duplication of Flt3 receptor gene was examined in a previous study . All acute leukemia samples contained over 90% blast cells with over 90% viability as assessed by the Trypan blue exclusion test.
Generation of cells expressing wild-type and mutant Flt3
The expression vector pCDHF3, containing a full-length cDNA of the Flt3 gene (designated as pCDHF3 ± Flt3) was kindly provided by Dr O Rosnet (Inserum, France) (Rosnet et al., 1991a) . The full-length cDNA of mutant Flt3 was Signal cascades activated by Flt3 F Hayakawa et al obtained as described previously . Concisely, MunI ± EcoRV fragments covering the tandem repeat of the mutated Flt3 cDNA were ampli®ed from two AML samples by RT ± PCR using the primer pairs, MunI-F (5'-CAACAATTGGTGTTTGTCTCCTCTT-3') and EcoRV ± R (5'-CATGATATCTCGAGCCAATCCAAAG-3'). Ampli®ed products were digested by a combination of MunI and EcoRV endonucleases, and puri®ed by agarose gel. The puri®ed mutated fragments were recombinated into the pCDHF3 ± Flt3. These full-length cDNAs of wild-type and mutant Flt3 gene were then cloned into pMKITneo vector (provided by Dr T Kitamura) containing NeoR gene. The inserts were sequenced by auto sequencer (ABI Prism 310 Genetic Analyzer; Perkin Elmer, Foster City, CA, USA). These vectors were electroporated in Gene Pulser Cuvettes (Bio-Rad Laboratories, Richmond, CA, USA) into cells with 300 Volts, 960 mF. Single cell clones were isolated at limiting dilution with selection with 800 mg/mL neomycin and maintained for further analysis.
Flow cytometric analysis of Flt3 expression
Cells were washed twice with phosphate-buered saline, incubated with an anti-Flt3 monoclonal antibody (SF1.340; Immunotech, France), followed by¯uorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG antibody (Coulter, Hialeah, FL, USA), then analysed on a¯ow cytometer (Epics XL; Coulter).
Analysis of cell growth and viability
Cells were washed with RPMI 1640 containing 10% FCS three times and then resuspended with the same medium alone or supplemented with 100 ng/mL of IL-3 or 100 ng/mL of Flt3 ligand (Pepro Tech EC Ltd, London, UK). Cell growth was calculated with the viable cell numbers detected by Trypan blue exclusion test. Cell viability was determined by counting viable versus dead cell numbers by propidium iodide exclusion method as described previously (Brodsky et al., 1999) .
Extraction of cell lysates
Whole cell lysates were obtained as described previously (Hayakawa et al., 1998) . Brie¯y, cells were lysed in lysis buer (20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2% Triton X-100, 0.5% sodium deoxycholate, 10 mM EDTA, 5 mM MgCl 2 ) containing 2 mM Na 3 VO 3 , 40 mM sodium pyrophosphate, 50 mM NaF, 20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mM benzamidine, and 1 mM phenylmethylsulfonyl¯uoride (PMSF). After incubating for 1 h at 48C, an equal volume of lysis buer without NaCl, Triton X-100 and sodium deoxycholate was added to the extracts which were then centrifuged at 17 000 g for 20 min. The concentration of the lysates was examined using Bio-Rad protein assay reagent (Bio-Rad, Munich, Germany).
Nuclear extracts were obtained as described previously (Wen et al., 1995) except that the same phosphatase inhibitors used for the whole cell extraction were added to lysis buers for nuclear extraction.
Immunoprecipitation and immunoblotting
Anti-ERK1, anti-ERK2 and anti-Flt3, rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-STAT5 and anti-phosphotyrosine (PY-20) mouse monoclonal antibodies were obtained from Transduction Laboratories (Lexington, KY, USA). Anti-phospho STAT5 rabbit polyclonal antibody was from New England Biolabs (Beverly, MA, USA).
Mobility shift analysis to dissect the phosphorylated forms of ERK1/ERK2 from the unphosphorylated forms was conducted as described previously (Towatari et al., 1997) . Equivalent amounts of protein were immunoprecipitated with anti-Flt3, anti-Lyn, or PY20 antibodies. Immunoprecipitants or nuclear extracts were subjected to 8% SDS ± PAGE as described previously (Hayakawa et al., 1998) . The blot was probed with speci®c antibody and visualized with epichemiluminescence Western blotting system (Amersham, Buckinghamshire, UK).
Gel shift assay
Gel shift experiments were performed as described (Wakao et al., 1994) . The MGF binding site of the bovine b-casein gene promoter (5'-AGATTTCTAGGAATTCAAATC-3') was used as a probe in gel shift assays. Anti-STAT5 antibody for supershift assay was obtained from Dr H Wakao (Helix Research Institute, Japan) (Hayakawa et al., 1998) .
